HC Wainwright Analysts Lower Earnings Estimates for LENZ

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Equities researchers at HC Wainwright reduced their Q2 2026 earnings estimates for LENZ Therapeutics in a research report issued on Tuesday, May 12th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($1.28) for the quarter, down from their prior estimate of ($1.06). HC Wainwright currently has a “Buy” rating and a $38.00 price objective on the stock. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($3.91) per share. HC Wainwright also issued estimates for LENZ Therapeutics’ Q3 2026 earnings at ($1.15) EPS, Q4 2026 earnings at ($0.99) EPS, FY2026 earnings at ($4.74) EPS and FY2027 earnings at ($3.73) EPS.

LENZ Therapeutics (NASDAQ:LENZ) last announced its earnings results on Monday, May 11th. The company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.22). LENZ Therapeutics had a negative net margin of 519.30% and a negative return on equity of 46.82%. The business had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.76 million.

LENZ has been the topic of a number of other research reports. Wall Street Zen cut shares of LENZ Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. William Blair reiterated an “outperform” rating on shares of LENZ Therapeutics in a report on Tuesday, March 10th. Citigroup cut their price target on shares of LENZ Therapeutics from $26.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday. Piper Sandler cut shares of LENZ Therapeutics from an “overweight” rating to a “neutral” rating and cut their price target for the company from $39.00 to $12.00 in a report on Tuesday. Finally, Bank of America dropped their target price on shares of LENZ Therapeutics from $35.00 to $29.00 and set a “buy” rating on the stock in a report on Wednesday, March 25th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, LENZ Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.80.

LENZ Therapeutics Stock Up 1.8%

NASDAQ:LENZ opened at $8.05 on Thursday. The company’s 50 day moving average price is $10.13 and its 200-day moving average price is $16.81. LENZ Therapeutics has a 52 week low of $6.83 and a 52 week high of $50.40. The stock has a market cap of $252.37 million, a price-to-earnings ratio of -2.24 and a beta of 0.62.

Institutional Trading of LENZ Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Tower Research Capital LLC TRC raised its position in shares of LENZ Therapeutics by 51.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company’s stock valued at $41,000 after purchasing an additional 477 shares during the period. Quarry LP bought a new stake in shares of LENZ Therapeutics during the 3rd quarter valued at $27,000. Bfsg LLC bought a new stake in shares of LENZ Therapeutics during the 3rd quarter valued at $30,000. Rhumbline Advisers raised its position in shares of LENZ Therapeutics by 2.7% during the 3rd quarter. Rhumbline Advisers now owns 25,019 shares of the company’s stock valued at $1,165,000 after purchasing an additional 656 shares during the period. Finally, JPMorgan Chase & Co. raised its position in shares of LENZ Therapeutics by 8.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 11,222 shares of the company’s stock valued at $523,000 after purchasing an additional 861 shares during the period. 54.32% of the stock is currently owned by institutional investors.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.